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With an objective of deﬁning potential diagnostic and/or therapeutic markers and the
mechanism of cellular transformation, we present a comparative proteomic study of
B-lymphocytes from B-cell acute lymphoblastic leukemia (B-ALL) patients and normal
controls, using two-dimensional gel electrophoresis and MALDI ToF/ToF tandem mass spec-
trometry. Our study led to the identiﬁcation of 79 differentially regulated proteins in the
malignant cells including proteins participating in proteostasis, cytoskeletal organization,
redox homeostasis, and signal transduction pathways relevant to leukemogenesis. Principal
component analysis displayed immunophenotype-/genotype-dependent variations in the
malignant cell proteome. Our study adds new insights to the leukemogenic B-cell biology
and  prognostic stratiﬁcations.
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signiﬁcant de-regulation of proteins participating in pro-
teostasis, cytoskeletal organization, cellular energy and redox
homeostasis, signal transduction, RNA splicing, and regula-
tion of transcription, in the malignant B-cells. Multivariate
statistics and principal component analysis (PCA) revealed
immunophenotype-/genotype-dependent variations in the 4637.
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prognostic stratiﬁcations. Overall, we  believe our data will
advance the ﬁeld of B-cell proteomics.
1.  Introduction
B-cell acute lymphoblastic leukemia (B-ALL) is the most com-
mon  cancer in children, characterized by an accumulation
of B-cell blasts that fail to differentiate. Immunopheno-
typing results establish that B-lineage leukemias dominate
amongst lymphoid leukemias in both children (where >80%
ALLs are B-ALLs) and adults (>75%). Gene fusions like TEL-
AML1, BCR-ABL, E2A-PBX1 and MLL  rearrangements, created
by chromosomal translocations are involved in the gene-
sis of B-ALL. In human B-ALLs, BCR-ABL and MLL-involving
translocations presumably originate in early progenitors (HSC
or lymphoid-myeloid progenitor), while TEL-AML1- and E2A-
PBX1-harbouring leukemic cells seem to represent more
differentiated, lymphoid-committed precursors [1]. Although
identiﬁcation of such genetic abnormalities has led to an
improved understanding of B-ALL pathophysiology, the mech-
anisms responsible for B-cell developmental arrest remain
unknown. The primary oncogenic events seem to require sec-
ondary cooperative changes to generate a fully transformed
cell. Contemporary therapies cure more  than 80% of children
with B-ALL but, some patients fall in high risk or poor progno-
sis classes requiring intensive treatment, others exhibit drug
resistance and many  patients develop serious acute and late
complications owing to drug toxicity. Furthermore, the sur-
vival rate for adults with B-ALL remains below 40% despite
the use of transplantation, and treatment outcome is poor
among patients who  relapse on current front-line ALL regi-
mens [2]. Current research focuses on the identiﬁcation of new
molecular targets to improve outcome for B-ALL patients with
a dismal prognosis [3].
Proteomic studies for the identiﬁcation of proteins aber-
rantly expressed in malignant B-cells can potentially be
used to develop new diagnostic, prognostic or therapeu-
tic targets. Transcriptome data on genome-wide expression
does not necessarily translate to protein expression pat-
terns, which warrants direct characterization of the malignant
cell proteome. Proteomic studies of B-cell malignancies have
made signiﬁcant progress, but further studies are needed to
increase the coverage of B-cell malignant proteome and to
unveil new insights in B-cell biology [4]. Two-dimensional gel
electrophoresis (2DGE) and, difference in-gel electrophoresis
(DIGE) using ﬂuorescent cyanide (Cy) dyes offer in essence a
2-step approach to separating complex protein mixtures in
accurate quantitative details and identify differences between
normal and aberrant cells.
The proteome is strongly inﬂuenced by cell differentiation.
A simple comparison of mononuclear cells (MNCs) from differ-
ent patients may result in the identiﬁcation of proteins whose
apparent change in expression actually reﬂects a difference
in the cellular composition of the specimens. Polypeptide
differences between abnormally proliferating cells could
be lineage related or could reﬂect, in part, the selective
activation of genes that are not expressed in normal cells. To
prevent such a complication and eliminate population-shift
effects, we compared the proteome proﬁles of B-lymphoblasts s 3 ( 2 0 1 4 ) 13–26
separated on the basis of their surface expression of CD19 and
CD10. Comparison of such background-matched fractions
should eliminate pseudopositive data resulting from different
proportions of leukemic blasts or from differences in cell
lineage to which the leukemic blasts are committed. Our
choice of CD antigens was based on the information that
early precursor-B cells express CD10 and CD19, and as the
precursor-B stage ends, CD10 is no longer expressed [5].
With a 2DGE followed by MALDI ToF/ToF tandem mass
spectrometry approach, our work presents a comparative pro-
teomic study of a homogeneous population of CD19+ cells
from 27 B-ALL patients and 10 normal controls that led to
the identiﬁcation of 79 differentially regulated proteins. Gene
ontology (GO) based functional annotation revealed signiﬁ-
cant de-regulation of proteins participating in proteostasis,
cytoskeletal organization, cellular energy and redox homeo-
stasis, signal transduction, RNA splicing, and regulation of
transcription, in the malignant cells. Multivariate statistics
and principal component analysis (PCA) revealed genetic
anomaly dependent variations in the malignant cell proteome.
We have discussed how the interactome of the observed de-
regulations could propose research avenues for addressing
the altered B-cell biology. Furthermore, candidate proteins
that exhibit opposite trend of de-regulation in myeloid and
lymphoid leukemia might not only point out prospective
biomarkers but also enhance our knowledge on the regulation
of differentiation of HSC into myeloid or lymphoid lineages.
2.  Materials  and  methods
2.1.  B-ALL  patient  samples  and  enrichment  of  CD19+
cells
Bone marrow and peripheral blood samples were obtained
from B-ALL patients with their informed written consents
(guardians in case of minors), following the guidelines of the
Institutional Ethical Committee of Vivekananda Institute of
Medical Sciences, Ramakrishna Mission Seva Pratishthan and
Institutional Animal & Bioethics committee of Saha Institute
of Nuclear Physics. The research was conducted according
to the principles expressed in the Declaration of Helsinki.
Clinical characteristics of individual patient samples are pro-
vided in Supplementary Material 1. All patient samples were
ﬁrst analysed for their immunophenotypes and only samples
with more  than 60% of CD19+/CD10+ B-cells were selected
for the study. The rationale for this selection criterion was
to ascertain high sample homogeneity in terms of their
immunophenotype, far-off from the normal range of <15%
B-cells in healthy individuals. 4–10 ml  of peripheral blood
samples and 1–3 ml  of bone marrow specimens from B-ALL
patients were used for isolation of CD19+ cells. Leukemic
blasts were isolated by density gradient centrifugation using
Histopaque®-1077 (Sigma, St. Louis, MO, USA) following the
manufacturer’s protocol; the CD19+ cells enriched by immuno-
magnetic separation (Miltenyi Biotec, Germany) and were
>95% pure as determined by ﬂow cytometry employing anti-
CD19-FITC antibody. For immunomagnetic separation, cells
were washed with PBS and re-suspended in minimal volume
of ice cold PBS, pH-7.2, 0.5% BSA, 2 mM EDTA. Next, cells were
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abelled with 20 l of CD19 micro beads per ≤107 total cells and
ncubated at 4 ◦C for 30 min. Then the cell suspension is passed
hrough the MACS  mini column and labelled cells ﬂushed out
f the iron mesh by pushing the plunger into the column.
95% pure normal human CD19+ B-lymphocytes were sorted
rom Mononuclear Cells of normal individuals using FACS
mploying anti CD19+ antibody. The normal control samples
ere either peripheral blood samples from normal volunteers
ertiﬁed to be medically ﬁt and healthy by our clinical col-
aborators (7 out of 10 samples) or bone marrow specimens
btained from patients reporting with persistent fever and
ody ache but eventually showed no signs of leukemia in their
eports (3 out of 10 samples). Nevertheless, the age and sex of
he normal volunteers was comparable with our B-ALL patient
ohort as evident from Table 1. We used ∼100 ml  of peripheral
lood samples and 1–3 ml  of bone marrow specimens from
ormal individuals for isolation of control/reference CD19+
ells. We  sorted CD19+ cells from normal control samples
sing FACS because the percentage of CD19+ B-cells in normal
amples is very low (8–12%). We  had to use larger volumes
f blood/bone marrow to retrieve 106 cells required for our
omparative proteomics study. The mini MACS  (magnetic cell
orting) module from Miltenyi Biotech that we used for B-
LL samples with very high percentages of CD19+ B-cells,
ould efﬁciently process smaller sample volumes. Thus we
ecided to use FACS employing the same anti-CD19 anti-
ody as in MACS  for faster and efﬁcient isolation of B-cells
rom normal samples. On the contrary, using FACS for B-ALL
atient samples would have required superﬂuous dilution of
he blood/bone marrow specimens. We  ensured ≥95% purity
f the CD19+ B-cells post enrichment, irrespective of whether
ACS or FACS based enrichment was employed.
.2.  2DGE,  staining  and  image  analysis
rotein lysates prepared from pure CD19+ cells (106 cells) were
e-suspended in 350 l of 2D rehydration buffer (7 M urea, 2 M
hiourea, 2% CHAPS, 0.05% 3–10 ampholyte, 20 mM DTT, from
io-Rad; and Protease inhibitor from Roche Diagnostics). The
rotein concentrations of the 27 B-ALL and 10 normal samples
ere estimated using RC DC protein estimation kit (Bio-Rad),
nd an absolute amount of ∼1.8 mg  for Coomassie staining,
r ∼600 g for silver staining, or ∼1.2 mg  for SYPRO RUBY
taining, was taken to 2DGE for each of the 37 (27 B-ALL + 10
Table 1 – Clinical characteristics of B-ALL patients and normal c
Normal contro
Sample Size (n) 10 (2DGE) + 3 (DIGE) + 2 (W
Age (years), mean ± SE 17.9 ± 3.8 
Males/Females, n 7/8 
Sample type 9/15- PB; 6/15- BM 
Haemoglobin (g/dL), mean ± SE 12.8 ± 2.5 
Leukocytes (×103/mm3), mean ± SE 7.5 ± 1.1 
Immunophenotype
(% ± SD)
13.2  ± 3.2% CD19+ cells, 
8.5 ± 2.1% CD2+/CD3+ cells
74.9 ± 5.3% CD13+/CD14+/C
SE: standard error; SD: standard deviation; n: number; g/dL: gram per deci
WB: western blot. 3 ( 2 0 1 4 ) 13–26 15
normal) samples. 17 cm pH 4–7 IPG strips (Bio-Rad) were
passively rehydrated or cup-loaded with the protein samples.
IEF was carried out in a Protean IEF cell (Bio-Rad), stepwise
up to 120,000 Volt-Hours. Equilibration of the strips post IEF
was performed following published protocol [6]. The second
dimension was run on 8–16% polyacrylamide gradient gels in
a Protean II XL electrophoresis module (Bio-Rad). Gels were
stained either with Blue Silver Coomassie [7] or SYPRO-RUBY
(Molecular Probes) according to manufacturer’s instructions,
or Silver stain according to the method used earlier [6]. Image
captures and analyses were done on Versa Doc series 3000
imaging system using PDQuest software (version 7.1, Bio-Rad).
Each of the 27 patient and 10 normal samples was subjected
to 3 analytical replicates. The triplicate gels from each sample
were combined and the resulting master gels were used for
densitometric comparisons and analyses. Densitometry anal-
ysis of the gel spots of interest was done using the density tool
of PDQuest. Spot volume (intensity) of the desired spot(s) was
normalized as parts per million (ppm) of the total spot volume
using the spots that were present in all gels, to calculate the
relative abundance of a spot in a sample. Although different
stains with appropriate sensitivities were used to visualize
the B-cell protein proﬁles of different normal and B-ALL
individuals, depending on the sample volumes available, all
the densitometric comparisons were done with similarly
stained gels; for e.g. coomassie stained normal vs. coomassie
stained B-ALL, silver stained normal vs. silver stained B-ALL,
etc. Supplementary material 2 gives an account of the stains
used for 27 B-ALL and 10 Normal samples. Sample label boxes
in the top row ﬁlled in blue indicate that at least 2/3 gels
for that sample were coomassie stained; sample label boxes
ﬁlled in tan and orange respectively indicate that at least 2/3
gels for that sample were silver or SYPRO RUBY stained.
2.3.  Data  analysis
For statistical evaluation of the differences observed in 2DGE,
densitometry data were subjected to both parametric stu-
dent’s t-test and non-parametric Wilcoxon-Mann–Whitney
test. Multivariate Principal Component Analysis (PCA) was
done using XLSTAT version 7.5.2 to assess the quantitative
differences and their contributions in discriminating normal
and B-ALL populations. For PCA only the 61 differentially
expressed proteins, as analysed in all 2DGE proﬁles, were
considered.
ontrols.
ls B-ALL
B) 27 (2DGE) + 3 (DIGE) + 4 (WB)
16.7 ± 1.9
15/19
3/34- PB; 28/34- BM; 3/34- PB & BM
6.2 ± 0.3
87.6 ± 10.8
23/34 samples- CD10+ high/CD19+ high/CD13−
, 4/34 samples- CD10+  int/CD19+ high/CD13−
D15+ cells 7/34 samples- CD10+  l◦w/CD19+  high/CD13+
liter; mm3: cubic milimetre; PB: peripheral blood; BM: bone marrow;
o m i c16  e u  p a o p e n p r o t e 
2.4.  CyDye  labelling,  DIGE  and  image  analysis
Total protein was extracted from CD19+ cells using sample
lysis buffer (7 M urea, 2 M Thiourea, 30 mM Tris, 4% CHAPS,
1 mM PMSF and 1% protease inhibitor cocktail). After esti-
mation of protein concentration, equal amounts of protein
sample from 3 normal and 3 B-ALL CD19+ cells were used for
three subsequent DIGE experiments. Proteins were labelled
with CyDye Fluor minimal dyes (GE Healthcare) according
to the manufacturer’s protocol. The internal standard (IS)
comprised a pooled equal amount from normal and B-ALL
experimental samples. A total of 80 g of protein from the nor-
mal  and B-ALL samples were labelled with 400 pmol of either
Cy3, Cy5, or Cy2 (Cy2 was used to label the IS). The labelled
mixtures were combined, cleaned up using 2D-CleanUp kit
(Bio-Rad), and then re-suspended in 2D rehydration buffer
prior to IEF and subsequent SDS-PAGE. All electrophoresis pro-
cedures were performed in the dark. 17 cm pH 4–7 IPG strips
(Bio-Rad) were cup-loaded with the labelled protein samples.
IEF was carried out in a Protean IEF cell (Bio-Rad), stepwise
up to 120,000 Volt-Hours. Equilibration of the strips post IEF
was performed following published protocol [6]. The second
dimension was run on 8–18% polyacrylamide gradient gels in
a Protean II XL electrophoresis module (Bio-Rad). Gels were
scanned using a TyphoonTM Trio Series Variable Mode Imager
(GE Healthcare) at 100 m resolution, followed by SYPRO-RUBY
staining. The resulting gel images generated from triplicate
gels were analysed using Differential In gel Analysis (DIA)
module of DeCyder software version 6.5 (GE Healthcare).
2.5.  In-gel  tryptic  digestion  and  mass  spectrometry
Sequencing grade trypsin was purchased from Promega (Madi-
son, WI). All other reagents were purchased from Pierce
(Rockford, USA). The protein spots from Coomassie and
SYPRO-RUBY stained 2D gels were excised using a robotic
spot-cutter (Bio-Rad). The gel pieces were de-stained with
50% acetonitrile, 25 mM ammonium bicarbonate. Subsequent
in-gel tryptic digestion, peptide elution, acquisition of MS
and MS/MS  spectra and database searches were done fol-
lowing our published protocol employing MALDI-TOF/TOF
tandem mass spectrometry [6]. Peak lists were prepared from
MS  and MS/MS  data using GPS explorer version 3.6 (Applied
Biosystems) software and noise reduction and de-isotoping
were performed using default settings. Resulting PMF  and
MS/MS  data were searched against human MSDB and Swiss-
Prot databases using in-house MASCOT version 2.1 (Matrix
Science, UK) server and MOWSE  score (with p < 0.05) was
considered to determine signiﬁcant hits. Sequence coverage
was determined from database match of the PMF/MS data.
For homologous proteins having similar MOWSE  scores, pref-
erence was given to the protein with best match between
theoretical and experimental molecular weight and pI. All MS
experiments were repeated at least thrice, with spots excised
from three separate gels. The database search parameters
included one missed cleavage, error tolerance of ±100 ppm for
PMF  and ±1.2 Da for MS/MS  ion search and variable modiﬁca-
tions like carbamidomethyl cysteine, methionine oxidation,
and N-terminal acetylation. s 3 ( 2 0 1 4 ) 13–26
2.6.  Western  immunoblotting
Cells were harvested and lysates recovered by centrifuga-
tion. After estimating the protein concentrations of 4 B-ALL
and 2 normal samples using RC DC protein estimation kit
(Bio-Rad), an absolute amount of ∼15 g for each of the 6
samples were separated by 15% SDS-PAGE and transferred on
PVDF. Blots were probed with respective primary and HRP-
conjugated secondary antibodies and developed by using ECL
detection system (Thermo Fisher Scientiﬁc, Rockford, IL, USA).
Primary antibodies for HSP-90, BiP, HSP-60, nucleophosmin,
peroxiredoxin-2, TCTP, protein disulﬁde isomerase, superox-
ide dismutase-1, and -actin and anti-rabbit or anti-mouse
HRP-conjugated secondary antibodies were either purchased
from Abcam, Cambridge, MA, USA or from Cell Signaling Tech-
nology, Inc., Danvers, MA 01923.
3.  Results
3.1.  De-regulated  CD19+ cell  proteome  in  B-ALL
As shown in the representative immunophenotypes in Fig. 1A,
leukemic cells obtained from bone marrow or peripheral
blood samples of the B-ALL patients showed CD19-CD10 co-
expression and thereby revealed the malignant clone to be
of precursor B-cells. Although the clinical details of many
B-ALL patients lacked cytogenetic data, it could be pre-
dicted from multiparametric immunophenotyping [8–10]. The
immunophenotypes (Supplementary Material 1) of about 60%
patients were indicative of TEL-AML1 chromosomal translo-
cation (scatter plot on left in Fig. 1A), while rest indicated
presence of BCR-ABL, MLL (scatter plot on right), or E2A-PBX1
translocations (middle scatter plot). Table 1 presents a sum-
mary as well as comparison of the clinical characteristics of
B-ALL patient cohort and normal reference cohort.
Supplementary material related to this article
can be found, in the online version, at doi:10.1016/j.
euprot.2014.01.002.
Fig. 1B shows representative ﬁltered images of 2D gels
for CD19+ cells from B-ALL patients and normal controls
and Fig. 1C shows a ﬂowchart depicting the strategy of our
differential proteomic study. Most polypeptides in 2D gels
occurred as part of recognizable spot-constellations. These
constellations were uniformly identiﬁable in gel patterns of
different cell types and served as landmarks. A compar-
ison of the immunophenotypes as well as the proteome
proﬁles of B-lymphoblasts, derived from bone marrow and
peripheral blood samples for few patients (Supplementary
Material 1), revealed very similar patterns with no signiﬁcant
differences in spot densities. PDQuest based densitometric
comparison of the 27 B-ALL and 10 normal proteome pro-
ﬁles, followed by parametric and non-parametric statistical
evaluation of observed differences (student’s t-test, Wilcoxon-
Mann–Whitney test) identiﬁed >100 spots that showed a
signiﬁcant and consistent difference in abundance between B-
ALL and normal proteomes. Peptide mass ﬁngerprinting and
tandem mass spectrometry by MALDI ToF/ToF of these spots
resulted in the identiﬁcation of the corresponding 60 pro-
teins differentially regulated in the leukemic B-lymphocytes,
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Table 2a – List of 60 differentially regulated proteins and the internal control -actin in B-ALL CD19+ B-cells, identiﬁed from 2DGE.
Spot no. Protein name Fold change p-Value Mascot
score
MW (kD) pI Sequence
coverageb
MS/MS
matches
t-test WMW  test
1 DnaK-type molecular chaperone HSPA5 precursor (BiP protein)a 2.74 0.028 0.015 503 72 5.03 58% 6
2 Haematopoietic lineage cell speciﬁc protein HS1 3.04 0.0265 <0.001 108 54 4.74 48% 4
3 Ubiquilin 1 3.26 0.0367 0.003 191 62.5 5.02 37% 6
4 Heat shock protein 60a 4.64 0.0296 <0.001 312 61 5.7 61% 6
5 Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) 2.7 0.0388 0.046 215 71 5.37 31% 4
6 Protein disulﬁde isomerasea 2.71 0.0138 0.015 245 57 4.76 62% 7
7 ATP synthase beta chain, mitochondrial precursor 2.98 0.0454 0.033 563 56.5 5.26 73% 11
8 Tubulin b 3.49 0.0344 0.002 436 49.6 4.78 57% 10
9 Heterogeneous nuclear ribonucleoprotein F 2.7 0.0149 0.003 171 46 5.38 51% 3
10 Actin beta 1.01 0.5961 0.369 275 40.98 5.56 67% 4
11 Protein disulﬁde isomerasea 3 0.0092 0.011 120 57 6.1 58% 7
12 D-3-phosphoglycerate dehydrogenase 2.68 0.034 0.026 215 56.5 6.31 36% 6
13 Phosphopyruvate hydratase (Alpha enolase) 4.82 <0.0001 <0.001 227 47 6.99 38% 7
14 Heterogeneous nuclear ribonucleoprotein H3 3.75 0.0034 <0.001 219 49 5.89 65% 3
15 Growth factor receptor-bound protein 2 (SH2/SH3 adaptor GRB2) 2.14 0.0392 0.041 109 25.19 5.89 34% 3
16 Glutathione S-transferase 3.14 <0.0001 <0.001 296 23.2 5.44 46% 3
17 Prohibitin 3.75 0.0243 0.020 192 30 5.57 55% 5
18 Peroxiredoxin 3 + peroxiredoxin 6
5.08  0.0405 0.002
94  27.6 7.67 27% 3
129 24.9 6.02 65% 6
19 Alternative splicing factor ASF-1 4.98 <0.0001 <0.001 108 22.5 7.72 48% 4
20 Heterogeneous nuclear ribonucleoprotein C1/C2 2.67 0.0332 0.011 329 32 5.1 65% 5
21 Vimentin 7.56 <0.0001 <0.001 50 53.5 5.06 38% –
22 Fascin 2 4.92 0.0281 0.008 59 55 7.95 20% 1
23 Rho GDP dissociation inhibitors Ly-GDI + Rho GDI 1+ Rho GDI 2
3.2  0.0315 0.015
179  23.2 5.02 34% 3
167 22.97 5.1 74% 3
24 Ubiquitin carboxyl terminal hydrolase 6.6 0.0216 0.003 85 26.2 4.84 53% 3
25 Peroxiredoxin 2a 8.25 <0.0001 <0.001 255 21.75 5.67 49% 2
26 HSP 27+ proteasome subunit b3 + proteasome endopeptidase complex 5.6 0.0049 0.003
123  22.77 5.98 40% 3
112 22.93 6.14 49% 3
72 25.88 6.92 58% 3
27 GrpE protein homolog 1, mitochondrial precursor 7.36 0.0026 0.011 89 24.26 8.24 52% 2
28 Nucleoside diphosphate kinase A 5.69 0.0385 0.041 186 17.14 5.83 76% 3
29 Stathmin (phosphoprotein p19) 7.29 <0.0001 <0.001 211 17.16 5.77 62% 3
30 Prefoldin subunit 2 3.54 0.0035 0.002 145 16.64 6.2 53% 4
31 Translationally controlled tumour protein (TCTP)a 4.12 0.0034 0.003 70 19.58 4.84 50% 4
32 TGFb- induced anti-apoptotic factor 1 6.22 <0.0001 <0.001 57 12.41 8.35 80% 1
33 SH3 domain binding protein SH3BP-1 3.34 0.0114 0.011 66 10.43 4.82 47% 1
34 Glutaredoxin-related protein C14 or f87 6.78 <0.0001 <0.001 93 16.62 6.28 35% 2
35 Enhancer of rudimentary homolog 3.61 <0.0001 <0.001 91 12.25 5.63 46% 1
36 Superoxide Dismutase (SOD)a 3.82 <0.0001 <0.001 93 15.8 5.7 30% 2
37 Endoplasmin precursor + HSP 90 betaa −2.66 <0.0001 <0.001 50  92.41 4.76 20% 2
220 83.08 4.97 36% 5
38 Mitoﬁlin −2.33 0.0004 0.005 61 83.63 6.08 32% 1
18
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Table 2a (Continued)
Spot no. Protein name Fold change p-Value Mascot
score
MW  (kD) pI Sequence
coverageb
MS/MS
matches
t-test WMW  test
39 Ezrin(Cytovillin) −3.76 <0.0001 <0.001 139  69.23 5.95 35% 3
40 Vinculin (Metavinculin) −4.72 <0.0001 0.006 56  123.59 5.51 21% 2
41 L-plastin(lymphocyte cytosolic protein 1) −5.85 <0.0001 <0.001 98  70.25 5.2 50% 1
42 Serum albumin precursor −4.98  <0.0001 <0.001 124 69.32 5.92 32% 3
43 UV excision repair protein RAD23 homolog −2.2 0.0107 0.011 179 43.15 4.79 23% 4
44 T-complex protein 1 subunit beta (TCP-1- b) −4.91 <0.0001 <0.001 134 57.32 6.02 71% 5
45 Stomatin like protein 2 SLP-2) −3.11 <0.0001 <0.001 168 38.52 6.88 51% 5
46 F-actin capping protein alpha-1 subunit (CapZ alpha1) −1.67 0.0421 0.041 90 32.9 5.45 52% 5
47 Inorganic pyrophosphatase −1.94 0.0025 0.003 242 32.64 5.54 49% 6
48 Nucleophosmina −2.97 <0.0001 0.001 261 32.44 4.67 45% 5
49 Tropomyosin 3 + Tropomyosin 2 (beta) −2.88 <0.0001 <0.001 218  28.91 4.72 47% 4
160 32.76 4.64 44% 3
50 Annexin A5 −2.03 0.0448 0.049 61 35.78 4.94 46% 1
51 Proliferating cell nuclear antigen (PCNA) −2.38 0.0045 0.008 83 28.75 4.57 46% 2
52 Clathrin light polypeptide (Lca) −3.02 <0.0001 <0.001 119 23.65 4.45 35% 2
53 Lactoylglutathione lyase (Methylglyoxalase, Aldoketomutase) −3.2 <0.0001 <0.001 134 20.58 5.25 36% 4
54 PACAP protein (Pituitary adenylate cyclase-activating polypeptide receptor) −2.56 0.0105 0.003 102 20.68 5.37 70% 2
55 Transcription elongation factor B polypeptide 2 −2.72 <0.0001 0.002 57 13.13 4.73 19% 2
56 Programmed cell death protein 5 (TFAR19 protein) −6.28 <0.0001 <0.001 101 14.15 5.78 67% 1
57 Translation initiation factor eIF-2B alpha subunit (eIF-2B GDP-GTP exchange factor) −3.78 <0.0001 <0.001 54 33.69 6.9 29% 3
58 Triosephosphate isomerase −2.42 0.0017 0.003 340 26.52 6.51 64% 9
59 Cytochrome c oxidase subunit Va (COX5A protein) −3.32 <0.0001 <0.001 117 16.75 6.3 54% 5
60 Peptidylprolyl isomerase −1.93 0.0096 0.005 85 17.87 7.82 73% 1
61 Fatty acid binding protein (FABP) −2.84 0.0015 0.005 157 15.02 6.84 76% 3
a Differential expression/regulation of these proteins were validated by western blot.
b Sequence coverage is based on database match of PMF/MS spectra/peak lists.
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Fig. 1 – (A) Three representative immunophenotypes of leukemic cells from B-ALL patients, indicative of TEL-AML1 (left),
E2A-PBX1 (middle) and MLL  (right) chromosomal rearrangements. (B) Representative 2DGE proﬁles of normal and B-ALL
CD19+ B-cell proteomes showing 35 up-regulated proteins (green), 25 down-regulated proteins (red) and the internal control
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f which 35 were up-regulated and rest down-regulated. The
pot for -actin did not show any signiﬁcant difference in
xpression between B-ALL and normal B-cell proteomes, and
ence chosen as the internal control. Table 2a provides a
ist of the differentially regulated proteins together with the
verage fold changes, p-values and summary of mass spec-
rometry identiﬁcation. The mass spectrometry data have
een submitted to the PRIDE database [11] and are avail-
ble at http://tinyurl.com/3wq7m49. Supplementary Material
 contains the densitometry and statistical details of the
ata.
Supplementary material related to this article can
e found, in the online version, at doi:10.1016/j.euprot.
014.01.002.
.2.  PCA  revealed  immunophenotype/genotype-
ependent  malignant  proteome
or optimum analysis of proteome data, a proper approach
or selection of signiﬁcant spots is a combination of univari-
te and multivariate analysis that highlights the variation of
ach of the differentially regulated proteins with respect to
hat in others in a holistic perspective. Hence, for a compre-
ensive analysis of the dataset, we  employed multifactorial
CA to evaluate the quantitative changes in protein expression
btained on analysing 2DGE data. Supplementary Material 3
rovides details of the PCA performed. Fig. 2A illustrates the
patial distribution of gel samples and protein spots using aential proteomic study. (For interpretation of the references
rsion of the article.)
2D PCA-biplot-space projection. Fig. 2B displays the projection
of eigenvectors for the protein variables present in the same
space deﬁned by PC1 and PC2.
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2014.01.002.
Additionally, PCA revealed immunophenotype/genotype-
dependent variations in the malignant cell proteome. All 3
B-ALL samples with immunophenotypes indicative of E2A-
PBX1 translocations and 11 samples out of 18 indicative of
TEL-AML1 immunophenotype were located on the upper side
of PC 2 whereas, all 6 samples indicative of BCR-ABL/MLL
immunophenotypes and rest 7 out of 18 indicative of TEL-
AML1 immunophenotype were located on the lower side of
PC 2. Overall, the group on the upper side of PC2 in the
biplot consisted of 14 B-ALL samples with immunophenotypes
indicative of TEL-AML1/E2A-PBX1 translocations and 78.5% of
these patients were below 15 years of age; while the group
on the lower side comprised 13 B-ALL patients, including all
samples indicative of MLL/BCR-ABL rearrangements and 69%
of these patients were above 15 years of age.
3.3.  Independent  2D-DIGE  analysis  conﬁrmed
de-regulations  in  B-ALL  CD19+ cell  proteomeThe results obtained in 2DGE were further conﬁrmed in
separate 2D-DIGE experiments using sensitive ﬂuorescent
dyes. Scanned images from 3 independent DIGE experiments
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Fig. 2 – (A) Spatial distribution of gel samples and protein spots using a 2D PCA-biplot-space projection. (B) Projection of
eigenvectors for the protein variables in the space deﬁned by PC1 and PC2. N1-N10: Normal controls; B1-B27: B-ALL patient
samples (circles, squares and stars respectively represent patient samples with TEL-AML1, E2A-PBX1 and BCR-ABL/MLL
d prindicating immunophenotypes); 1–61: Differentially regulate
were subjected to DeCyder based analysis. Fig. 3 shows a
representative scanned image  and the reference 2D map  of
CyDye-labelled B-ALL and normal B-cell proteomes obtained
on DIA analysis. Supplementary Material 4 summarizes
the DIA analysis results enlisting more  than 300 spots that
showed a signiﬁcant difference in expression level of moreoteins.
than two-fold, between B-ALL and normal B-cell proteomes.
MALDI ToF/ToF tandem mass spectrometry led to the identi-
ﬁcation of corresponding 79 proteins, which included the 60
proteins that were identiﬁed to be differentially expressed in
2DGE experiments with comparable fold changes. Table 2b
enlists the 19 new differentially regulated proteins identiﬁed
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Fig. 3 – (A) Representative scanned image for DIGE of B-ALL vs. normal CD19+ B-cell proteome. (B) Reference 2D map  of
CyDye-labelled B-ALL and normal B-cell proteomes obtained on DIA analysis showing de-regulated proteins
(green→up-regulated, red→down-regulated) and those with similar abundances (yellow). (C) Histogram plot for log volume
ratios in the DIA workspace. (D) 3D view of individual spots of a down-regulated protein (nucleophosmin) and an
up-regulated protein (HSP 60) in normal and B-ALL CD19+ B-cell proteome maps. (For interpretation of the references to
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n DIGE experiments, along with the respective average
olume ratio obtained on DIA analysis.
Supplementary material related to this article can
e found, in the online version, at doi:10.1016/j.euprot.
014.01.002.
.4.  GO  annotation  unveiled  major  de-regulation  of
roteostatic,  cytoskeletal  and  redox  proteins
he functional classiﬁcation of the identiﬁed proteins was
chieved following gene ontology in DAVID, UniProt and
ANTHER databases, and is summarized in Fig. 4A. The
ifferentially expressed proteins are involved in impor-
ant biological functions. As evident from Fig. 4A, most
f the differentially regulated proteins (33%) are associated
ith protein homeostasis i.e. proteostasis (protein folding,on of the article.)
transport/translocation and proteasomal degradation). The
next majority (17%) participates in cytoskeletal organiza-
tion followed by those involved in cellular energy and redox
homeostasis (13%). Rest is involved in signal transduction,
RNA splicing, regulation of transcription and other cellular
activities. As can be extrapolated from Fig. 4B, a huge pro-
portion of the stress response proteins including the redox
regulators, chaperones and those associated with protea-
somal degradation, are up-regulated in B-ALL CD19+ cells,
while proteins involved in protein transport/translocation are
down-regulated; cytoskeletal and signal transduction pro-
teins show both up- and down-regulation trends. Further,
most of the de-regulated proteins associated with macro-
molecular metabolism and energy homeostasis show higher
abundance in B-ALL. The differentially regulated proteins
were also classiﬁed according to their cellular localization as
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Table 2b – List of 19 additional differentially regulated proteins in B-ALL CD19+ B-cells, identiﬁed from 2D-DIGE.
Sr no. Protein ID Average volume
ratio
Mascot
score
Sequence
coveragea
Number of
MS/MS
matches
1 Galactokinase 1 +2.64 76 39% 4
2 Cytokeratin 10 +2.2 74 28% 2
3 Translation initiation factor eIF-4B +2.4 141 46% 5
4 Lymphocyte speceﬁc protein 1 +2.35 71  53% 3
5 Heterogeneous nuclear ribonucleoprotein K +4.75 129  54% 3
6 150kD oxygen regulated protein (Orp150, hypoxia up-regulated
1)
−3.17  49 24% 2
7 Moesin −2.24 69 30% 3
8 Tat-binding protein 1 −3.4 251 65% 4
9 H+-transporting two sector ATPase +2.03 188 52% 8
10 ATP synthase D chain, mitochondrial +20.75 117 76% 1
11 Proteasome alpha 5 subunit +20.44 86 39% 3
12 78kD glucose-regulated protein precursor (GRP78) −3.37 271 47% 5
13 60S acidic ribosomal protein P2 +2.65 52 86% 1
14 Homo sapiens cargo selection protein TIP47 −10.69 302 66% 5
15 Stress-70 protein, mitochondrial precursor (75kD glucose
regulated protein – GRP75)
+2.59  376 46% 9
16 EIF3S4 protein +2.34 61 60% 3
17 Dynactin subunit 2 −2.83 260 62% 6
18 PTB associated splicing factor +3.16 140 39% 3
19 Galectin-1 +8.11 86 76% 2
peaka Sequence coverage is based on database match of PMF/MS spectra/
detailed in Fig. 4C. This classiﬁcation shows that our protein
identiﬁcations were not restricted to any particular cellular
compartment and represent normal subcellular distribution.
3.5.  Validation  by  western  immunoblotting
To conﬁrm the results obtained from 2DGE experiments,
we quantitated the amounts of eight differentially regulated
proteins in raw plasma, obtained from a set of 2 normal con-
trols and 4 B-ALL patients, using western immunoblotting.
Fig. 5 shows the immunoblots for 8 proteins with -actin
as loading control, and histogram plot of the band intensi-
ties. All data were subjected to unpaired two-tail student’s
t-test and the changes were found to be signiﬁcant (p ≤ 0.01).
The immunoblots clearly supported results from 2DGE exper-
iments.
4.  Discussion
B-ALL is still a poorly understood disease primarily because
of higher survival rates compared to other leukemias. Hence,
it is noteworthy that a comparative study of the molecular
proﬁle of such good prognosis leukemia with that of the
poor outcome leukemias will pave the way to identifying
the causes of prognostic stratiﬁcation. Signiﬁcant differences
between primary tumour cells and immortalised cell lines
emphasize the importance of obtaining protein proﬁling data
from primary malignant B-cells. In our study, random sam-
pling of B-ALL patients irrespective of their genetic subtypes
left us with a scope of outlining the relationship between
various chromosomal translocations and the differentially
regulated B-cell proteome in a ‘bottom-up’ approach. To eval-
uate quantitative alterations of protein spots, and to search lists.
for co-regulated proteins that might help in interpreting the
mechanism of leukemogenesis, we utilized PCA in addition
to parametric/non-parametric statistical assessments. PCA of
the differentially regulated proteins detected in 2DGE, enabled
to separate the ‘good-prognosis’ TELAML1/E2A-PBX1 phe-
notypes from those with the ‘poor-prognosis’ MLL/BCR-ABL
chromosomal rearrangements with a good efﬁciency. Thus,
PCA mediated delineation of genotype dependent proteome
alterations may be useful in assessing B-ALL prognosis. Clus-
ter analysis of the protein expression proﬁles using Cluster
3.0 and TreeView (Supplementary data 5) showed signiﬁcant
differences between normal and diseased samples and sig-
niﬁcant clustering for most of the B-ALL sample phenotypes.
Nevertheless separation of diseased samples was easier to
be visualized in the PCA results. Proteins above PC2 in Fig. 2B
seem to be the downstream targets of TEL-AML1/E2A-PBX1
induced cellular transformation and those below PC2 may par-
ticipate in MLL/BCR-ABL induced malignancy. Interestingly,
all of the redox up-regulations stay conﬁned to the good-
prognosis malignant cell proteome (above PC2). This indicates
that the poor-prognosis B-ALL cells use an alternative mech-
anism to combat oxidative stress and utilize it favourably,
plausibly explaining for the reduced susceptibility of such
patients to chemotherapeutic agents (e.g. daunorubicin, vin-
cristine, prednisone) that utilize oxidative stress and resulting
cytotoxicity. Metabolic coupling of leukemic cells and their
stromal microenvironment allows reactive oxygen species
(ROS) generated from leukemic cells to induce glycolytic-shift
(Warburg effect) and autophagy in stromal cells and thereby
recycle nutrients for growth of leukemic cells in a ‘parasitic’
manner [12]. Thus providing an alternative mechanism of
how the poor-prognosis B-ALL leukemic cells survive in spite
of oxidative stress. Nevertheless, excess ROS may promote
mutagenesis and genomic instability, driving co-evolution of
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Fig. 4 – (A) Pie distribution of GO based functional classiﬁcation of the de-regulated proteins. (B) Histogram plot of the fold
changes of spot densities for the 60 de-regulated proteins with a colour scheme representing functional classiﬁcation as in
(A); error bars represent SE of the fold changes across 37 samples. (C) Pie distribution of GO based subcellular localization of
the de-regulated proteins. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
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eukemic cells and stroma [12]. De-regulation of major mito-
hondrial proteins like ATP synthase, cytochrome oxidase,
SP60, and prohibitin observed in the high-risk malignant
roteome point towards mitochondrial dysfunction and
herefore a more  aggressive phenotype [12]. Investigating ATP
eneration and oxidative stress management in high-risk
-ALL may be a topic of future research. Novel therapeutic
trategies designed to metabolically uncouple leukemic
ells from their surrounding stroma might improve clinical
utcome in poor-prognosis B-ALL patients.
Supplementary material related to this article can
e found, in the online version, at doi:10.1016/j.euprot.
014.01.002.
Some of the observed de-regulations (HSP-60, HSP-90,
ranslationally controlled tumour protein or TCTP, Superox-
de dismutase or SOD, protein disulﬁde isomerase or PDI, BiP,
eroxiredoxin 2 or PRDX2, and nucleophosmin or NPM) were
urther conﬁrmed by immunoblot based validation experi-
ents using a separate set of 2 normal and 4 B-ALL samples(Fig. 5). Additionally, comparison of our data with microar-
ray based gene expression proﬁles of B-ALL cells, available in
ArrayExpress, NCBI [13], revealed ∼75% agreement between
proteomic and transcriptomic trends (Supplementary Mate-
rial 6).
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2014.01.002.
Functional partnerships between proteins are at the core of
complex cellular phenotypes. We used the STRING database
[14] to analyse the functional relation between the de-
regulated proteins and key kinases, adaptor proteins and epi-
genetic regulators involved in pre-B-cell fate decisions [15–18].
STRING in protein mode was used, and only interactions with
high conﬁdence levels (>0.7) were kept. Supplementary Mate-
rial 7 represents a graphical view of the interactome deduced
from STRING. Supplementary Material 8 enlists plausible
implications of the de-regulated proteins in B-ALL accord-
ing to the STRING interactome and previous reports. On the
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Fig. 5 – (A) Immunoblots for 8 proteins with -actin as loading control in two normal controls (N14-N15) and four B-ALL
samples (B31-B34). (B) Histogram plot of the band intensities in (A); All data were subjected to unpaired two-tail student’s
t-test and the changes were  found to be signiﬁcant (p ≤ 0.01) indicated by **. TCTP – Translationally Controlled Tumour
Protein; HSP–Heat Shock Protein; SOD1 – Superoxide Dismutase 1; PDI – Protein Disulﬁde Isomerase; BiP – DnaK-type
 – Numolecular chaperone HSPA5; PRDX2 – Peroxiredoxin 2; NPM
basis of the STRING interactome and available literature, Fig. 6
summarizes how the de-regulated proteins identiﬁed in this
study may contribute to leukemogenesis. B-cell linker protein
(BLNK/SLP-65) down-regulation has been crucially linked to
the differentiation block involved in pre-B-ALL. Alternative
splicing of the SLP-65 gene transcript has been implicated
in regulation of SLP-65 expression [17]. Our data shows
deregulation of several spliceosome proteins that provides
one mechanism to explain B-ALL pathogenesis. Leukemic
cells are exposed to chronic metabolic stress that triggers
ER stress by accumulation of misfolded proteins. The cells
adapt to this stress by reducing protein synthesis, facilitating
ER-associated protein degradation (ERAD) using the ubiquitin-
proteasome and autophagy-lysosome systems, expanding the
size of the ER through augmented lipid biosynthesis, and
increasing production of chaperones [19], as reﬂected in
major de-regulation of proteostasis machinery observed in our
study.
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2014.01.002.
Nucleophosmin (also known as NPM/B23) is a ubiqui-
tously expressed nucleolar phosphoprotein that constantly
shuttles between the nucleus and cytoplasm. NPM contains
distinct functional domains through which it performs manycleophosmin.
functions in the cell related to both proliferation and growth
suppression pathways. It participates in the process of ribo-
some biogenesis, and controls genetic stability through the
regulation of centrosome duplication. As a result, NPM overex-
pression correlates with uncontrolled cell growth and cellular
transformation, whereas the disruption of NPM expression
can cause genomic instability and centrosome ampliﬁca-
tion, which increases the risk of cellular transformation.
NPM is implicated in human tumorigenesis. It is frequently
overexpressed in AML [20]. In our study, we observed down-
regulation of NPM in B-ALL cells. Transcriptome data available
in ArrayExpress, NCBI [13] also advocate NPM down-regulation
in ALL as opposed to its up-regulation in AML. Addition-
ally, we  observed NPM down-regulation in lymphoma cell
line DG75 in contrast to NPM up-regulation in promyelocytic
leukemia cell line HL60, using DIGE (Supplementary Material
9). Depending on its expression levels and gene dosage, NPM
seems to function as either an oncogene or a tumour sup-
pressor in myeloid and lymphoid lineages respectively. Either
partial functional loss or aberrant overexpression could lead
to neoplastic transformation through distinct mechanisms
[20].Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2014.01.002.
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Fig. 6 – Chart illustrating the link between the de-regulated proteins, crucial B-cell signalling mediators and leukemogenic
signal transduction pathways.
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